CAMYO 02
Alternative Names: CAMYO-02Latest Information Update: 21 Dec 2023
At a glance
- Originator myNEO
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Triple negative breast cancer
Most Recent Events
- 21 Dec 2023 CAMYO 02 is available for licensing (https://myneotx.com/)
- 04 Dec 2023 Early research in Triple-negative-breast-cancer in Belgium (Parenteral) (Prior to December 2023) (myNEO pipeline, December 2023)